Sorrento Therapeutics, Inc. has entered into an exclusive licensing agreement to develop and commercialize multiple biosimilar antibodies from Mabtech Ltd., a holding company for antibody development and manufacturing companies in China.   Sorrento will develop and market four monoclonal antibodies (mAbs) for the North American, European and Japanese market. Each of the mAbs has completed a Phase III study; two are currently in registration for approval in China, while the other two are under ...